Duke University

Uti Limited Partnership

Serenex, Inc.

Timothy A J Haystead

Philip Floyd Hughes

Emily Derbyshire

Douglas Weitzel

Justin A MacDonald

Michael P Walsh

David A Carlson

George J Young

Khaldon Bodoor

The present disclosure is directed to compounds that may selectively inhibit Death Associated Protein Kinases (DAPKs) as well as PIM kinases. The compounds can be used in methods of treating various disorders, including cancers.

Kinase inhibitors and related methods of use

The present invention provides inhibitors of TAK1 having formula (I) and methods of using such compounds to treat various diseases.

Substituted benzimidazoles as inhibitors of transforming growth factor-&#x3b2; kinase

Described herein are compounds that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. The compounds may allow for selective detection of Hsp90 in a sample.

Compounds and methods for targeting HSP90

The present invention provides inhibitors of TAK1 having formula (II), affinity resins, and fluorescent dyes and methods of using such compounds to treat various diseases or in protein isolation or purification. 

The present invention provides novel inhibitors of TAK1 having formula (I) and methods of using such compounds to treat various diseases. 

Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-&#x3b2; kinase and methods of use thereof

Inducible HSP70 is overexpressed in a wide spectrum of human tumors and its expression correlates with metastasis and poor outcomes to radiation and chemotherapy in patients. Identification of small molecule inhibitors of HSP70 pose a new therapy to cancer treatment. HS72, a benzimidazole piperidinyl carboxamide has been identified as an allosteric inhibitor for HSP70 and has demonstrated good tumor growth inhibition in vivo.

Heat shock protein 70 (hsp-70) receptor ligands

A method and apparatus are described for screening a proteome. The method and apparatus include an array of affinity elements, such that a proteome is directed through the array and those components that specifically bind to the affinity elements of the array are eluted in a suitable eluent by means of centrifugation. Suitable eluents can include a proteome component, a chemical library component or an affinity element. This method and apparatus can be used for several purposes, including screening for bio-active compounds, determining physiological targets of known drugs, determining specificity of compound interactions with physiological targets, and for quantitative protein analyses.

Growing community of inventors

Chapel Hill, NC, United States of America

Timothy A J Haystead